Sectors & IndustriesHealthcare

Best Healthcare Stocks to Buy Now (2026)

Top healthcare stocks in 2026 ranked by overall Due Diligence Score. See the best healthcare stocks to buy now, according to analyst forecasts for the healthcare sector.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best healthcare stocks to buy right now are:

Tactile Systems Technology (NASDAQ:TCMD) is the #1 top healthcare stock out of 1075 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Tactile Systems Technology (NASDAQ:TCMD) is: Value: B, Growth: B, Momentum: C, Sentiment: B, Safety: C, Financials: A, and AI: C.

Tactile Systems Technology (NASDAQ:TCMD) has a Due Diligence Score of 59, which is 32 points higher than the healthcare sector average of 27. It passed 19 out of 33 due diligence checks and has strong fundamentals. Tactile Systems Technology has seen its stock return 60.9% over the past year, overperforming other healthcare stocks by 88 percentage points.

Tactile Systems Technology has an average 1 year price target of $37.33, an upside of 66.44% from Tactile Systems Technology's current stock price of $22.43.

Tactile Systems Technology stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Tactile Systems Technology, 66.67% have issued a Strong Buy rating, 0% have issued a Buy, 33.33% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Amneal Pharmaceuticals (NASDAQ:AMRX) is the #2 top healthcare stock out of 1075 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Amneal Pharmaceuticals (NASDAQ:AMRX) is: Value: B, Growth: A, Momentum: C, Sentiment: A, Safety: C, Financials: C, and AI: B.

Amneal Pharmaceuticals (NASDAQ:AMRX) has a Due Diligence Score of 30, which is 3 points higher than the healthcare sector average of 27. It passed 10 out of 33 due diligence checks and has average fundamentals. Amneal Pharmaceuticals has seen its stock return 73.87% over the past year, overperforming other healthcare stocks by 101 percentage points.

Amneal Pharmaceuticals has an average 1 year price target of $17.00, an upside of 29.67% from Amneal Pharmaceuticals's current stock price of $13.11.

Amneal Pharmaceuticals stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Amneal Pharmaceuticals, 100% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Bioventus (NASDAQ:BVS) is the #3 top healthcare stock out of 1075 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Bioventus (NASDAQ:BVS) is: Value: B, Growth: A, Momentum: C, Sentiment: C, Safety: B, Financials: A, and AI: C.

Bioventus (NASDAQ:BVS) has a Due Diligence Score of 40, which is 13 points higher than the healthcare sector average of 27. It passed 13 out of 33 due diligence checks and has average fundamentals. Bioventus has seen its stock return 44.67% over the past year, overperforming other healthcare stocks by 72 percentage points.

Bioventus has an average 1 year price target of $15.00, an upside of 47.49% from Bioventus's current stock price of $10.17.

Bioventus stock has a consensus Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Bioventus, 0% have issued a Strong Buy rating, 100% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 72 healthcare stocks that have issued dividends in the past year, the 3 healthcare stocks with the highest dividend yields are:

So Young International (NASDAQ:SY) has an annual dividend yield of N/A, which is N/A percentage points lower than the healthcare sector average of 2.49%.

So Young International's dividend payout ratio of 0% indicates that its dividend yield might not be sustainable for the long-term.

Dominari Holdings (NASDAQ:DOMH) has an annual dividend yield of 21.11%, which is 19 percentage points higher than the healthcare sector average of 2.49%.

Dominari Holdings's dividend payout ratio of -42.4% indicates that its high dividend yield might not be sustainable for the long-term.

Siga Technologies (NASDAQ:SIGA) has an annual dividend yield of 12.96%, which is 10 percentage points higher than the healthcare sector average of 2.49%.

Siga Technologies's dividend payout ratio of 181.8% indicates that its high dividend yield might not be sustainable for the long-term.

Healthcare stocks were up 0.58% in the last day, and up 0.11% over the last week. Cns Pharmaceuticals was the among the top gainers in the healthcare sector, gaining 239.25% yesterday.

CNS Pharmaceuticals shares are trading higher after the company announced a $22.5 million private placement of 650,000 shares at $2.30 per share and warrants.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued healthcare stocks right now are:

Embecta (NASDAQ:EMBC) is the most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Embecta has a valuation score of 86, which is 71 points higher than the healthcare sector average of 15. It passed 6 out of 7 valuation due diligence checks.

Embecta's stock has dropped -25.76% in the past year. It has overperformed other stocks in the healthcare sector by 1 percentage points.

Ironwood Pharmaceuticals (NASDAQ:IRWD) is the second most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Ironwood Pharmaceuticals has a valuation score of 71, which is 56 points higher than the healthcare sector average of 15. It passed 5 out of 7 valuation due diligence checks.

Ironwood Pharmaceuticals's stock has gained 394.61% in the past year. It has overperformed other stocks in the healthcare sector by 422 percentage points.

Harmony Biosciences Holdings (NASDAQ:HRMY) is the third most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 71, which is 56 points higher than the healthcare sector average of 15. It passed 5 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has gained 8.78% in the past year. It has overperformed other stocks in the healthcare sector by 36 percentage points.

58.84% of healthcare stocks rated by analysts are a strong buy right now. On average, analysts expect healthcare stocks to rise by 40.06% over the next year.

5.09% of healthcare stocks have a Zen Rating of A (Strong Buy), 12.67% of healthcare stocks are rated B (Buy), 49.94% are rated C (Hold), 24.72% are rated D (Sell), and 7.58% are rated F (Strong Sell).